The Japan cancer vaccines market size was valued at USD 911.21 million in 2024. The market is projected to grow from USD 1,070.49 million in 2025 to USD 4,633.44 million by 2034, exhibiting a CAGR of 17.7% during 2025–2034.This growth is fueled by advances in immuno-oncology, increasing government support for cancer research, and growing investments by both domestic and international pharmaceutical firms.
Market Segmentation
To gain a comprehensive understanding of the Japan cancer vaccines market, it is segmented based on vaccine type, indication, technology, and end-user.
- By Vaccine Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Personalized Cancer Vaccines
- Oncolytic Virus-Based Vaccines
Preventive cancer vaccines, such as HPV and HBV vaccines, account for the largest market share, supported by renewed government-led awareness campaigns and national immunization programs. Meanwhile, therapeutic and personalized cancer vaccines are gaining traction as research advances and clinical trials expand. Oncolytic virus therapy, which uses genetically engineered viruses to selectively kill cancer cells, is an emerging segment gaining interest among biotech startups and academic institutions.
- By Indication
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Others (Colorectal, Ovarian, Breast Cancer)
Cervical cancer dominates the indication segment, driven by government efforts to increase HPV vaccination rates, which had declined significantly following public concerns in the early 2010s. Prostate, lung, and colorectal cancers are also key areas where therapeutic and personalized vaccine strategies are being explored.
- By Technology
- Dendritic Cell Vaccines
- DNA & RNA-based Vaccines
- Tumor Cell-Based Vaccines
- Protein/Peptide-Based Vaccines
- Viral Vector Vaccines
Among these, dendritic cell-based vaccines and mRNA-based cancer vaccines are witnessing strong research momentum. The success of mRNA vaccines in infectious diseases has accelerated their application in oncology, with Japanese companies and academic labs investing heavily in this area.
- By End-User
- Hospitals
- Cancer Research Centers
- Specialty Clinics
- Academic Institutes
Hospitals and cancer centers are the primary end-users, but academic institutions in Japan are playing an increasingly important role in early-stage research and clinical trials, especially in personalized vaccine development.
Regional Analysis
Japan’s cancer vaccines market demonstrates a strong concentration of R&D, clinical trials, and commercial activity in major metropolitan areas:
Tokyo Metropolitan Region
As the nation's biotech and pharmaceutical hub, Tokyo hosts major players such as Astellas, Chugai, and Takeda. Institutions like the University of Tokyo and the National Cancer Center lead the way in cancer immunotherapy research, with multiple clinical trials focused on personalized cancer vaccines and oncolytic viruses.
Osaka
Home to pharmaceutical giants like Shionogi and Daiichi Sankyo, Osaka is emerging as a critical region for vaccine production and commercialization. The Osaka University Medical School is also involved in several cancer immunotherapy studies and joint ventures.
Kyushu and Hokkaido
These regions are expanding their biotech infrastructure and are increasingly involved in clinical trials and government-supported initiatives. Local universities and startups are engaged in early-stage trials of dendritic cell therapies and peptide-based vaccines.
Market Drivers
- Rising Cancer Burden
Japan faces one of the world’s highest cancer incidence rates. An aging population, coupled with increased exposure to environmental and lifestyle risk factors, has led to a surge in demand for advanced treatment options like therapeutic and personalized cancer vaccines.
- Government Support and Policy
The Japanese government actively supports cancer vaccine development through initiatives such as the Basic Plan to Promote Cancer Control Programs and funding through the Japan Agency for Medical Research and Development (AMED). The reinstatement of HPV vaccination recommendations in 2022 is expected to boost the preventive vaccines segment significantly.
- Technological Innovation
Breakthroughs in genomics, AI-driven biomarker discovery, and nanotechnology are enabling the development of personalized cancer vaccines tailored to individual patients’ tumor profiles. mRNA and viral vector technologies are making vaccines more effective and easier to produce at scale.
- Global Partnerships and Collaborations
Collaborations between Japanese firms and international biotech companies are accelerating vaccine development. Partnerships between NEC and U.S.-based Transgene, as well as alliances involving Moderna and Takeda, are bringing next-generation vaccine candidates closer to commercialization.
Read More @ https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market
Market Trends
- Adoption of Personalized Cancer Vaccines
Personalized vaccines designed based on individual tumor neoantigens are showing promising clinical results, especially in melanoma and non-small cell lung cancer (NSCLC). Japan’s advanced genomic testing infrastructure supports the adoption of these vaccines.
- Oncolytic Virus Therapy Expansion
Japanese biopharma companies are increasingly exploring oncolytic virus therapy for its dual benefits—direct tumor lysis and stimulation of systemic immune response. Oncolys BioPharma is a notable player in this space, conducting several clinical trials with novel viral vectors.
- Integration with Checkpoint Inhibitors
Cancer vaccines are increasingly being studied in combination with immune checkpoint inhibitors like PD-1 and CTLA-4 blockers. These combinations aim to overcome tumor immune evasion and are being tested in trials across Tokyo and Osaka.
- AI in Vaccine Design
Japanese research institutions are leveraging artificial intelligence to identify tumor-specific antigens and optimize vaccine formulations, improving the effectiveness of therapeutic and personalized cancer vaccines.
Key Companies
Japan's cancer vaccines market features a blend of domestic leaders and global collaborators. Notable companies include:
Astellas Pharma
Actively involved in both preventive and therapeutic vaccines, Astellas is investing in immuno-oncology platforms and partnerships with international biotech firms.
Takeda Pharmaceutical
Takeda plays a key role in Japan’s HPV vaccination programs and is expanding its oncology pipeline through acquisitions and joint ventures, including mRNA and viral-based therapies.
Chugai Pharmaceutical (Roche Group)
Focuses on the development of advanced biologics and is involved in several immunotherapy studies including cancer vaccines in collaboration with its global partner, Roche.
Shionogi & Co.
Known for its vaccine manufacturing capabilities, Shionogi is exploring partnerships for cancer vaccine development, particularly mRNA and DNA platforms.
Oncolys BioPharma
A frontrunner in oncolytic virus therapy, the company is developing virotherapy-based cancer treatments with active trials in hepatocellular carcinoma and pancreatic cancer.
NEC Corporation
While primarily known as a tech firm, NEC is leveraging its AI capabilities to develop personalized cancer vaccines in collaboration with medical research institutes.
Challenges
Despite the optimistic outlook, the cancer vaccines market in Japan faces several challenges:
- High Development Costs: Personalized vaccines are expensive to develop, test, and manufacture, limiting access and scalability.
- Regulatory Hurdles: Long approval timelines and strict clinical trial requirements can delay commercialization.
- Public Skepticism: Historical vaccine hesitancy, particularly surrounding HPV, poses a challenge to widespread preventive vaccine adoption.
Opportunities
- Government Incentives: Subsidies and fast-track approval for breakthrough therapies offer favorable conditions for growth.
- Aging Population: A large elderly demographic creates sustained demand for cancer prevention and treatment.
- Emerging Technologies: AI, mRNA, and CRISPR-based platforms provide new frontiers for innovation and competitive differentiation.
Conclusion
The Japan cancer vaccines market is poised for significant growth as the country embraces cutting-edge biotechnology to combat rising cancer incidence. With strong government support, advanced R&D capabilities, and increasing private-sector investment, Japan is set to become a major hub for preventive, therapeutic, personalized, and oncolytic cancer vaccine innovation.
As scientific understanding deepens and technological tools evolve, cancer vaccines are moving from theoretical promise to clinical reality—offering new hope for patients across Japan and contributing meaningfully to global cancer control efforts.
More Trending Latest Reports By Polaris Market Research:
Aesthetic Medicine Market
Airway Management Devices Market
Alopecia Market
Alzheimer’s Therapeutics Market
Ambulatory Care Services Market
Sepsis Diagnostics Market